Screening for left ventricular dysfunction may have less value than thought

The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the Journal of Cardiac Failure.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news163937418.html">Screening for left ventricular dysfunction may have less value than thought</a></p> <p>The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the <i>Journal of Cardiac Failure</i>.</p>